Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 74,360 Shares of Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 74,360 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was purchased at an average cost of $11.85 per share, with a total value of $881,166.00. Following the acquisition, the director now owns 17,382,566 shares in the company, valued at $205,983,407.10. The trade was a 0.43 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, March 31st, Ecor1 Capital, Llc bought 4,397 shares of Zymeworks stock. The shares were bought at an average price of $11.75 per share, for a total transaction of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc acquired 43,848 shares of Zymeworks stock. The shares were bought at an average cost of $12.24 per share, for a total transaction of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The stock was purchased at an average price of $13.08 per share, with a total value of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc bought 31,033 shares of Zymeworks stock. The shares were purchased at an average cost of $12.78 per share, for a total transaction of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc acquired 58,306 shares of Zymeworks stock. The stock was acquired at an average price of $12.64 per share, for a total transaction of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc bought 56,277 shares of Zymeworks stock. The stock was bought at an average cost of $12.23 per share, for a total transaction of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The shares were bought at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc acquired 320,690 shares of Zymeworks stock. The shares were purchased at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The stock was acquired at an average price of $13.87 per share, with a total value of $273,904.76.
• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The shares were bought at an average price of $14.01 per share, with a total value of $546,796.29.

Zymeworks Stock Up 2.6 %

Shares of NYSE:ZYME traded up $0.30 on Wednesday, hitting $11.92. 523,406 shares of the company traded hands, compared to its average volume of 597,500. The stock has a 50 day simple moving average of $13.50 and a 200-day simple moving average of $13.73. The company has a market cap of $829.36 million, a PE ratio of -7.95 and a beta of 1.13. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70.

Institutional Trading of Zymeworks

A number of institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC raised its stake in Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after buying an additional 1,524 shares during the last quarter. AlphaQuest LLC lifted its holdings in Zymeworks by 480.2% in the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after acquiring an additional 2,324 shares during the period. FMR LLC boosted its position in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after purchasing an additional 1,525 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Zymeworks during the 4th quarter valued at about $108,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Zymeworks by 343.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after purchasing an additional 7,518 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

ZYME has been the topic of a number of research analyst reports. HC Wainwright boosted their price target on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Monday, March 10th. Lifesci Capital started coverage on Zymeworks in a report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 target price for the company. Citigroup boosted their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, March 7th. Wells Fargo & Company raised their target price on shares of Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.00.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.